Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
Baxter
Moodys
Mallinckrodt

Last Updated: June 29, 2022

Patent: 9,114,179


✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,114,179
Title:Immunoconjugate formulations
Abstract: The present invention provides an immunoconjugate formulation that is substantially free of particles, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of: sucrose, polysorbate 20, polysorbate 80, cyclodextrin, dextrose, glycerol, polyethylene glycol, mannitol, sodium chloride, and an amino acid, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention also provides an immunoconjugate formulation that is substantially free of aggregates, the immunoconjugate formulation comprising: an immunoconjugate and one or more excipients selected from the group consisting of histidine, sucrose, glycine and sodium chloride, wherein the formulation is a buffered aqueous solution having a pH of 4.5 to 7.6. The present invention further provides an immunoconjugate formulation that is substantially free of both particles and aggregates.
Inventor(s): Zhang; Wei (Philadelphia, PA), Fleming; Michael S. (Londonderry, NH), Amphlett; Godfrey (Cambridge, MA), Chih; Hung-wei (Burlingame, CA), Bartlett; Elizabeth (Cambridge, MA)
Assignee: ImmunoGen, Inc. (Waltham, MA)
Application Number:11/498,139
Patent Claims:see list of patent claims

Details for Patent 9,114,179

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 See Plans and Pricing 2025-08-03
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 See Plans and Pricing 2025-08-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 See Plans and Pricing 2025-08-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 See Plans and Pricing 2025-08-03
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 See Plans and Pricing 2025-08-03
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 See Plans and Pricing 2025-08-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Express Scripts
Mallinckrodt
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.